Last Update:
December 15, 2017
Documents identified with this
icon are in Portable Document Format (PDF) and require the
Adobe
Acrobat Reader
|
Journal Papers, Abstracts, and Commentaries
| |
Prevention of Hiv-1 Transmission Through
Breastfeeding: Efficacy and Safety of Maternal Antiretroviral
Therapy Versus Infant Nevirapine Prophylaxis for Duration of
Breastfeeding in Hiv-1-Infected Women with High Cd4 Cell Count (Impaact
Promise): A Randomized, Open Label, Clinical Trial.
Flynn PM, Taha TE, Cababasay M, et a'l
J Acquir Immune Defic Syndr.
2017 Dec 11
Abstract
Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for
Neonates.
Cressey TR, Punyawudho B, Le Coeur S, et a
J Acquir Immune Defic Syndr.
2017 May 9.
Abstract
Nevirapine Plasma Concentrations in Human Immunodeficiency Virus-Exposed
Neonates Receiving High-Dose Nevirapine Prophylaxis as Part of 3-Drug
Regimen.
Bolaris
MA, Keller MA, Robbins BL,
et
al
J Pediatric Infect Dis Soc. 2016 Jan 23.
Abstract
Risk of congenital cytomegalovirus infection among HIV-exposed uninfected
infants is not decreased by maternal nelfinavir use during pregnancy.
Gantt S, Leister E, Jacobson DL, et al
J Med Virol.
2015 Oct 31
Abstract
FULL-TEXT ARTICLE
A
cross-sectional study of the magnitude, barriers, and outcomes of HIV
status disclosure among women participating in a perinatal HIV
transmission study, "the Nevirapine Repeat Pregnancy study".
Kiweewa FM, Bakaki PM, McConnell MS,
et al
BMC Public Health. 2015
Sep 29;15(1):988.
Paper |
FULL-TEXT
ARTICLE
Nevirapine, Sodium Concentration and HIV-1 RNA in Breast Milk and Plasma among
HIV-Infected Women Receiving Short-Course Antiretroviral Prophylaxis.
Salado-Rasmussen K, Theilgaard ZP, Chiduo MG. et al
PLoS One. 2015 Mar
26;10(3):e0121111.
Paper
Reduction of nevirapine-driven HIV mutations by carbamazepine is modulated by
CYP3A activity.
Baranyai D, Muro E, Gödtel-Armbrust U, et al
J Antimicrob Chemother.
2014 Apr 2.
Abstract
FULL-TEXT PDF ARTICLE
Clonal
amplification and maternal-infant transmission of nevirapine-resistant HIV-1
variants in breast milk following single-dose nevirapine prophylaxis.
Permar SR, Salazar MG, Gao F, et al
Retrovirology.
2013 Aug 14;10(1):88.
Paper
Clinical and Genetic Determinants of Plasma Nevirapine Exposure following an
Intrapartum Dose to Prevent Mother-to-Child Transmission.
Vardhanabhuti S, Acosta EP, Ribaudo HJ,
et al
J Infect Dis.
2013 May 17
Abstract |
Facilitators and barriers to cotrimoxazole and nevirapine prophylaxis among HIV
exposed babies: a qualitative study from Harare, Zimbabwe.
Sibanda E, Weller I, Bernays S,et al .
J Int AIDS Soc. 2012 Nov 11;15 Suppl 4:18061
Abstract
Nevirapine Inhibits Cell-Free Human Immunodeficiency Virus (HIV)-1 Infection In
Vitro More Efficiently Than Cell-Cell HIV Infection at Concentrations Found in
Human Breastmilk.
Dorosko SM, Housman ML, Connor RI.
Breastfeed Med. 2012 Dec
18.
Abstract |
FULL-TEXT ARTICLE
Maternal CD4+ Cell Count Decline after Interruption of Antiretroviral
Prophylaxis for the Prevention of
Mother-to-Child Transmission of HIV.
Ekouevi D, Abrams EJ, Schlesinger M,
et al
PLoS One.
2012;7(8):e43750.
Paper
Population Pharmacokinetic Analysis of a Nevirapine-Based HIV-1
Prevention of Mother-to-Child Transmission
Program in Uganda to Assess the
Impact of Different Dosing Regimens for Newborns.
Frank M, Harms G, Kunz A, Kloft C.
J
Clin Pharmacol. 2012 May 25.
Abstract |
FULL-TEXT PDF LETTER
Transplacental passage
of nevirapine, nelfinavir and lopinavir.
van Hoog S, Boer K, Nellen J, et al
J Med. 2012 Mar;70(2):102-103.
Commentary |
Kinetics of nevirapine and its impact on HIV-1 RNA levels in maternal plasma and
breast milk over time
after perinatal single dose nevirapine.
Aizire J, McConnell MS,
Mudiope P, et al
J Acquir Immune Defic Syndr.
2012 Jan 1
Abstract
FULL-TEXT ARTICLE
Effectiveness of Non-nucleoside Reverse-Transcriptase Inhibitor-Based
Antiretroviral
Therapy in Women Previously Exposed to a Single Intrapartum Dose of Nevirapine:
A Multi-country, Prospective Cohort Study.
Stringer JS, McConnell MS, Kiarie J,
et al
PLoS Med.
2010 Feb 16;7(2):e1000233.
Paper |
Temporal reduction of HIV type 1 viral load in breast milk by
single-dose nevirapine
during prevention of MTCT.
Rossenkhan R, Ndung'u T, Sebunya TK, et al .
AIDS Res Hum Retroviruses.
2009 Dec;25(12):1261-4.
Abstract |
|
Tolerance and viral resistance after single-dose nevirapine with
tenofovir and emtricitabine to prevent
vertical transmission of HIV-1.
The TEmAA ANRS 12109 Study group.
AIDS. 2009 Mar 19.
Abstract
|
Extended-dose
nevirapine to 6 weeks of age for infants to prevent HIV transmission via
breastfeeding
in Ethiopia,
India, and Uganda: an analysis of three randomised controlled trials.
Six Week Extended-Dose Nevirapine (SWEN) Study Team.
Lancet. 2008 Jul
26;372(9635):300-313.
Abstract
|
|
| |
Constraints of implementing on a larger scale the protocol of
prevention of HIV/AIDS from
mother to child by Nevirapine intake
Adeothy-Koumakpai
S, Monnykosso CN, D'almeida M, et al
Arch Pediatr. 2004 Dec;11(12):1425-1429.
Abstract
Intrapartum Exposure to Nevirapine and Subsequent
Maternal Responses to
Nevirapine-Based Antiretroviral Therapy.
Jourdain G, Ngo-Giang-Huong N, Le
Coeur S, et al
N Engl J Med.
2004 Jul 9
Abstract
|
| |
Nevirapine: a review of its use in the prevention and treatment of
paediatric
HIV infection.
Bardsley-Elliot A, Perry CM.
Paediatr Drugs 2000 Sep-Oct;2(5):373-407
Abstract |
|
|
|
Journal Papers, Abstracts, and Commentaries
| |
Nevirapine Pharmacokinetics and Safety in Neonates
Receiving Combination Antiretroviral Therapy for Prevention of Vertical
HIV Transmission
Lau E, Brophy J, Samson L, Kakkar F,
J Acquir Immune Defic Syndr.
2017 Jan 20.
Abstract
Nevirapine prophylaxis to prevent HIV-1 mother-to-child transmission:
pharmacokinetic considerations in preterm infants.
Capretti MG, Marsico C, Conti M,
et al
New Microbiol. 2016
Jun 10;39(3).
Abstract
Pharmacokinetics of Injectable, Long-acting Nevirapine for HIV Prophylaxis in
Breastfeeding Infants.
Cortez JM Jr, Quintero R, Moss JA,
et al
Antimicrob Agents Chemother.
2014 Oct 13
Abstract
Population Pharmacokinetic Analysis of a Nevirapine-Based HIV-1 Prevention
of Mother-to-Child Transmission Program in Uganda to Assess the Impact of
Different Dosing Regimens for Newborns.
Frank M, Harms G, Kunz A, Kloft C.
J Clin Pharmacol. 2013 Mar;53(3):294-304
Abstract
Chronic administration of nevirapine during pregnancy: impact of pregnancy
on
pharmacokinetics.
Capparelli EV, Aweeka F, Hitti J, et al
HIV Med. 2008 Apr;9(4):214-220.
Abstract
|
Nevirapine: pharmacokinetic considerations in children and pregnant women.
Mirochnick M, Clarke DF, Dorenbaum A.
Clin Pharmacokinet 2000 Oct;39(4):281-93
Abstract
Pharmacokinetics of nevirapine in human immunodeficiency virus type
1-infected
pregnant women and their neonates. Pediatric AIDS Clinical Trials Group
Protocol 250
Team.
Mirochnick M, Fenton T, Gagnier et al
.
J Infect Dis 1998
Aug;178(2):368-74
Abstract
A phase I/II study of the safety and
pharmacokinetics of nevirapine in HIV-1-infected
pregnant Ugandan women and their neonates (HIVNET006).
Musoke P,
Guay LA, Bagenda D, et al,
AIDS
1999 Mar 11;13(4):479-86
Abstract |
|
|
Journal Papers, Abstracts, and Commentaries
|
Journal Papers, Abstracts, and Commentaries
|
Journal Papers, Abstracts, and Commentaries
|
Journal Papers, Abstracts, and Commentaries
|
|
Nevirapine
Pregnancy/Neonate Data |
|
New
and Noteworthy
Safety